CXN-8

CXN-8 is a small molecule derivative of pirfenidone developed as a dual-action bronchodilator and anti-inflammatory agent for the treatment of severe asthma. It specifically targets corticosteroid-insensitive neutrophilic airway inflammation and $\beta$2-adrenergic receptor-insensitive airway hyperresponsiveness. Mechanistically, CXN-8 acts by inhibiting RhoA activation, which restores myosin light chain phosphatase (MLCP) activity and reduces myosin regulatory light chain (MLC2) phosphorylation. This modulation of the calcium sensitization pathway leads to rapid airway relaxation. CXN-8 has demonstrated significantly higher potency (approximately 50-fold) compared to its parent compound, pirfenidone, in preclinical models.